Peritransplantation Use of Ruxolitinib in Myelofibrosis
Publication type: Journal Article
Publication date: 2020-12-01
SJR: —
CiteScore: —
Impact factor: —
ISSN: 10838791, 15236536
PubMed ID:
32818555
Hematology
Transplantation
Abstract
Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Annals of Hematology
2 publications, 33.33%
|
|
|
Expert Opinion on Emerging Drugs
1 publication, 16.67%
|
|
|
American Journal of Hematology
1 publication, 16.67%
|
|
|
Cancer Immunology, Immunotherapy
1 publication, 16.67%
|
|
|
Blood
1 publication, 16.67%
|
|
|
1
2
|
Publishers
|
1
2
3
|
|
|
Springer Nature
3 publications, 50%
|
|
|
Taylor & Francis
1 publication, 16.67%
|
|
|
Wiley
1 publication, 16.67%
|
|
|
American Society of Hematology
1 publication, 16.67%
|
|
|
1
2
3
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
6
Total citations:
6
Citations from 2024:
5
(83.34%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
ibrahim U. et al. Peritransplantation Use of Ruxolitinib in Myelofibrosis // Biology of Blood and Marrow Transplantation. 2020. Vol. 26. No. 12. pp. 2177-2180.
GOST all authors (up to 50)
Copy
ibrahim U., Petrone G. E. M., Mascarenhas J., Keyzner A. Peritransplantation Use of Ruxolitinib in Myelofibrosis // Biology of Blood and Marrow Transplantation. 2020. Vol. 26. No. 12. pp. 2177-2180.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.bbmt.2020.08.015
UR - https://doi.org/10.1016/j.bbmt.2020.08.015
TI - Peritransplantation Use of Ruxolitinib in Myelofibrosis
T2 - Biology of Blood and Marrow Transplantation
AU - ibrahim, uroosa
AU - Petrone, Giulia Eva Maria
AU - Mascarenhas, John
AU - Keyzner, Alla
PY - 2020
DA - 2020/12/01
PB - Elsevier
SP - 2177-2180
IS - 12
VL - 26
PMID - 32818555
SN - 1083-8791
SN - 1523-6536
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2020_ibrahim,
author = {uroosa ibrahim and Giulia Eva Maria Petrone and John Mascarenhas and Alla Keyzner},
title = {Peritransplantation Use of Ruxolitinib in Myelofibrosis},
journal = {Biology of Blood and Marrow Transplantation},
year = {2020},
volume = {26},
publisher = {Elsevier},
month = {dec},
url = {https://doi.org/10.1016/j.bbmt.2020.08.015},
number = {12},
pages = {2177--2180},
doi = {10.1016/j.bbmt.2020.08.015}
}
Cite this
MLA
Copy
ibrahim, uroosa, et al. “Peritransplantation Use of Ruxolitinib in Myelofibrosis.” Biology of Blood and Marrow Transplantation, vol. 26, no. 12, Dec. 2020, pp. 2177-2180. https://doi.org/10.1016/j.bbmt.2020.08.015.